Novel therapeutic agents for cutaneous T-Cell lymphoma

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Jain, Salvia ^a   Zain, Jasmine ^a   O'Connor, Owen ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BELINOSTAT; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CD4 ANTIBODY; CHEMOKINE RECEPTOR CXCR4; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZASTAURIN; FORODESINE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 6; LENALIDOMIDE; PANOBINOSTAT; PRALATREXATE; PREDNISONE; ROMIDEPSIN; SGN 30; VINCRISTINE; VORINOSTAT; ZANOLIMUMAB;

ANEMIA; ANOREXIA; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMATIN; CONSTIPATION; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DIARRHEA; DISEASE SEVERITY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ENZYME ACTIVITY; EPISTAXIS; FATIGUE; FEVER; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GRANULOCYTOPENIA; HISTONE ACETYLATION; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; IC 50; ILEUS; IMMUNOGENICITY; INFECTION; INJECTION SITE REACTION; LEG EDEMA; LOCAL SKIN REACTION; LYMPHOCYTOPENIA; MALAISE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYCOSIS FUNGOIDES; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; REMISSION; REVIEW; SENSORY NEUROPATHY; SEZARY SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SKIN BURNING SENSATION; SKIN INFECTION; SKIN NECROSIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY CAST; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MOLECULAR TARGETED THERAPY;

EID: 84861091081     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-24     Document Type: Review

References (110)

1. Cutaneous lymphoma incidence patters in the United States: a population based study of 3884 cases. Bradford PT, Devesa SS, Anderson WF, et al. Blood 2009 113 5064 5073 10.1182/blood-2008-10-184168 19279331
2. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization for research and treatment of cancer (EORTC). Olsen E, Vonderheid E, Pimpinelli N, et al. Blood 2007 110 1713 1722 10.1182/blood-2007-03-055749 17540844
3. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised international society for cutaneous lymphomas/European organization for research and treatment of cancer staging proposal. Agar NS, Wedgeworth E, Crichton S, et al. J Clin Oncol 2010 28 4730 4739 10.1200/JCO.2009.27.7665 20855822
4. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Kim YH, Liu HL, Mraz-Gernhard S, et al. Arch Dermatol 1996 139 857 866
5. Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach. Horwitz SM, Olsen EA, Duvic M, et al. J Natl Compr Canc Netw 2008 6 4 436 442 18433609
6. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Trautinger F, Knobler R, Willemze R, et al. Eur J Cancer 2006 42 8 1014 1030 10.1016/j.ejca.2006.01.025 16574401
7. How I treat mycosis fungoides and Sezary syndrome. Prince HM, Whittaker S, Hoppe RT, et al. Blood 2009 114 4337 4353 10.1182/blood-2009-07-202895 19696197
8. Long-term outcomes of patients with advanced stage cutaneous T-cell lymphoma and large cell transformation. Arulogan SO, Prince HM, Ng J, et al. Blood 2008 112 3082 3087 10.1182/blood-2008-05-154609 18647960
9. Clinical end points and response criteria in mycosis fungoides and sezary syndrome: a consensus statement of the International Society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European organization for research and treatment of cancer. Olsen EA, Whittaker S, Kim YH, et al. J Clin Oncol 2011 18 2598 2607
10. Epigenetic modifiers: basic understanding and clinical development. Piekarz R, Bates S, Clin Cancer Res 2009 15 3918 3926 10.1158/1078-0432.CCR-08- 2788 19509169
11. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Johnstone RW, Licht JD, Cancer Cell 2003 4 13 18 10.1016/S1535-6108(03)00165-X 12892709
12. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Sandor V, Senderowicz A, Mertins S, et al. Br J Cancer 2000 83 6 817 825 10.1054/bjoc.2000.1327 10952788
13. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. Sambucetti LC, Fischer DD, Zabludoff S, et al. J Biol Chem 1999 274 49 34940 34947 10.1074/jbc.274.49.34940 10574969
14. The retinoblastoma tumour suppressor in development and cancer. Classon M, Harlow E, Nat Rev Cancer 2002 2 12 910 917 10.1038/nrc950 12459729
15. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Gui CY, Ngo L, Xu WS, et al. Proc Natl Acad Sci USA 2004 101 5 1241 1246 10.1073/pnas.0307708100 14734806
16. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Richon VM, Sandhoff TW, Rifkind RA, et al. Proc Natl Acad Sci USA 2000 97 18 10014 10019 10.1073/pnas.180316197 10954755
17. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Peart MJ, Tainton KM, Ruefli AA, et al. Cancer Res 2003 63 15 4460 4471 12907619
18. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Ruefli AA, Ausserlechner MJ, Bernhard D, et al. Proc Natl Acad Sci USA 2001 98 19 10833 10838 10.1073/pnas.191208598 11535817
19. Chromatin modification, leukaemia and implications for therapy. Jones LK, Saha V, Br J Haematol 2002 118 3 714 727 12181038
20. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nebbioso A, Clarke N, Voltz E, et al. Nat Med 2005 11 1 77 84 10.1038/nm1161 15619633
21. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Guo F, Sigua C, Tao J, et al. Cancer Res 2004 64 7 2580 2589 10.1158/0008-5472.CAN-03-2629 15059915
22. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Butler LM, Zhou X, Xu WS, et al. Proc Natl Acad Sci USA 2002 99 18 11700 11705 10.1073/pnas.182372299 12189205
23. Acetylation of [beta]-catenin by CREB-binding protein (CBP). Wolf D, Rodova M, Miska EA, et al. J Biol Chem 2002 277 28 25562 25567 10.1074/jbc.M201196200 11973335
24. Acetylation of importin-a nuclear import factors by CBP/p300. Bannister AJ, Miska EA, Gorlich D, et al. Curr Biol 2000 10 8 467 470 10.1016/S0960- 9822(00)00445-0 10801418
25. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Cohen HY, Lavu S, Bitterman KJ, et al. Mol Cell 2004 13 5 627 638 10.1016/S1097-2765(04)00094-2 15023334
26. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Kim MS, Kwon HJ, Lee YM, et al. Nat Med 2001 7 4 437 443 10.1038/86507 11283670
27. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1a activity. Mie Lee Y, Kim SH, Kim HS, et al. Biochem Biophys Res Commun 2003 300 1 241 246 10.1016/S0006-291X(02)02787-0 12480550
28. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Marquard L, Gjerdrum LM, Christensen IJ, et al. Histopathology 2008 53 3 267 277 10.1111/j.1365-2559.2008.03109.x 18671804
29. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Mann BS, Johnson JR, Cohen MH, et al. Oncologist 2007 12 1247 1252 10.1634/theoncologist.12-10-1247 17962618
30. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm189629.htm
31. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells. Relevance to mechanism of therapeutic action. Zhang C, Richon V, Ni X, et al. J Invest Dermatol 2005 125 1045 1052 10.1111/j.0022-202X.2005.23925.x 16297208
32. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Kelly WK, Richon VM, OConnor OA, et al. Clin Cancer Res 2003 9 3578 3588 14506144
33. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. OConnor OA, Heaney ML, Schwartz L, et al. J Clin Oncol 2006 24 166 173 10.1200/JCO.2005.01.9679 16330674
34. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Duvic M, Talpur R, Ni X, et al. Blood 2007 109 31 39 10.1182/blood-2006-06-025999 16960145
35. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Olsen EA, Kim YH, Kuzel TM, et al. J Clin Oncol 2007 25 3109 3115 10.1200/JCO.2006.10.2434 17577020
36. The systemic effects of vorinostat in Patients with cutaneous T-cell lymphoma (CTCL): Post-Hoc analysis in patients with high blood tumor burden. Duvic M, Kim YH, Kuzel TM, Blood 2009 ASH Annual Meeting Abstracts 114:Abstract 1709
37. A novel regimen of vorinostat with interferon gamma for refractory Sezary syndrome. Gardner JM, Introcaso CE, Nasta SD, et al. J Am cad Dermatol 2009 61 112 116 10.1016/j.jaad.2008.11.889
38. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Piekarz RL, Robey RW, Zhan Z, et al. Blood 2004 103 4636 4643 10.1182/blood-2003-09-3068 14996704
39. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Piekarz RL, Robey RW, Sandor V, et al. Blood 2001 98 2865 2868 10.1182/blood.V98.9.2865 11675364
40. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Piekarz R, Frye R, Turner M, et al. J Clin Oncol 2009 27 5410 5417 10.1200/JCO.2008.21. 6150 19826128
41. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Whittaker S, Demierre MF, Kim EJ, et al. J Clin Oncol 2010 28 29 4485 4491 10.1200/JCO.2010.28.9066 20697094
42. New guidelines to evaluate the response to treatment in solid tumors: European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of canada. Therasse P, Arbuck SG, Eisenhauer EA, et al. J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437
43. Revised response criteria for malignant lymphoma. Cheson BD, Pfistner B, Juweid ME, et al. J Clin Oncol 2007 25 579 586 10.1200/JCO.2006.09.2403 17242396
44. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Stevens SR, Ke MS, Parry EJ, et al. Arch Dermatol 2002 138 42 48 10.1001/archderm.138.1.42 11790166
45. Clinical trials and efficacy assessment in the therapy of cutaneous T-cell lymphoma. Heald P, Ann NY cad Sci. 2001 941 155 165
46. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Olsen E, Duvic M, Frankel A, et al. J Clin Oncol 2001 19 376 388 11208829
47. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherpy: Preliminary result. Edelson R, Berger C, Gasparro F, et al. N Engl J Med 1987 316 297 303 10.1056/NEJM198702053160603 3543674
48. A phase I pharmacokinetic and pharmacodynamics study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Steele NL, Plumb JA, Vidal L, et al. Clin Cancer Res 2008 14 804 10.1158/1078-0432.CCR- 07-1786 18245542
49. Cardiac studies in patients with depsipeptide, FK28, in a phase II trial for T-cell lymphoma. Piekarz R, Frye R, Wright J, et al. Clin Cancer Res 2006 12 3762 3773 10.1158/1078-0432.CCR-05-2095 16778104
50. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Gimsing P, Hansen M, Knudsen LM, et al. Eur J Haematol 2008 81 170 176 10.1111/j.1600-0609.2008.01102.x 18510700
51. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Steele NL, Plumb JA, Vidal L, et al. Cancer Chemother Pharmacol 2011 67 1273 1279 10.1007/s00280-010-1419-5 20706839
52. Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors. Kelly WK, DeBono J, Blumenschein G, et al. J Clin Oncol (Meeting Abstracts) 2009 27 3531
53. Final results of a phase II trial of Belinostat (PXD-101) in patients with recurrent ore refractory peripheral or cutaneous T-cell lymphoma. Pohlman B, Advani RH, Duvic M, Blood 2009 ASH Annual Meeting Abstracts 114:Abstract 920
54. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Ellis L, Pan Y, Smyth GK, et al. Clin Cancer Res 2008 14 4500 4510 10.1158/1078-0432.CCR-07-4262 18628465
55. Phase II trial of Oral Panobinostat in patients with refractory Cutaneous T-cell Lymphoma. Duvic M, Becker JC, Dalle S, Blood 2008 ASH Annual Meeting Abstracts 112:Abstract1005
56. Pan-histone deacetylase (HDAC) inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic anti-myeloid activity in combination with CXCR4 antagonists. Mandawat A, Fiskus W, Buckley KM, et al. Blood 2010 116 24 5306 5315 10.1182/blood-2010-05-284414 20810927
57. Molecular and biological characteristics of acquired vorinostat-resistant cutaneous T-cell lymphoma cells. Zhang C, Zhang X, Li B, Blood 2009 ASH Annual Meeting Abstracts 114:Abstract 1732
58. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Fotheringham S, Epping MT, Stimson L, et al. Cancer Cell 2009 15 57 66 10.1016/j.ccr.2008.12.001 19111881
59. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Khan O, Fotheringham S, Wood V, et al. Proc Natl Acad Sci U S A 2010 107 6532 6537 10.1073/pnas.0913912107 20308564
60. Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). OConnor OA, Pro B, Pinter-Brown LL, J Clin Oncol 2009 27 15s suppl; abstr 8561 10.1200/JCO.2008.21.7695
61. New folate analogs of the 10-deaza-aminopterin series: Basis for structural design and biochemical and pharmacologic properties. Sirotnak FM, DeGraw JI, Moccio DM, et al. Cancer Chemother Pharmacol 1984 12 18 25 6690069
62. Activity of a novel antifolate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Wang ES, OConnor OA, She Y, et al. Leuk Lymphoma 2003 44 1027 1035 10.1080/1042819031000077124 12854905
63. Distince mechansistic activity profile of pralatrexate in comparison to other antifolates in vitro and in vivo molds of human cancers. Izbicka E, Diaz A, Saunders M, et al. Cancer Chemother Pharmacol 2009 64 993 999 10.1007/s00280-009-0954-4 19221750
64. Pralatrexate is an effective treatment for heavily pretreated patients with relapsed/refractory transformed mycosis fungoides (tMF). Foss FM, Horwitz SM, Brown LP, Blood 2010 ASH Annual Meeting Abstracts 116:Abstract 1762
65. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL): Final results of a multicenter dose-finding study. Horwitz SM, Kim YH, Foss FM, Blood 2010 ASH Annual Meeting Abstracts 116:Abstract 2800
66. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Enrica Marchi, Luca Paoluzzi, Luigi Scotto, et al. Clin Cancer Res 2010 16 14 3648 3658 10.1158/1078-0432.CCR-10-0671 20501616
67. Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. Ri M, Iida S, Ishida T, et al. Cancer Sci 2009 100 341 348 10.1111/j.1349-7006.2008.01038.x 19068089
68. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. Richardson PG, Sonneveld P, Schuster MW, et al. New Engl J Med 2005 352 2487 2498 10.1056/NEJMoa043445 15958804
69. Phase II clinical experience with the novel proteasome inhibitor bortezomib inpatients with indolent non-Hodgkins lymphoma and mantle cell lymphoma. OConnor OA, Wright J, Moskowitz C, et al. J Clin Oncol 2005 23 676 684 10.1200/JCO.2005.02.050 15613699
70. The proteasome: a suitable antineoplastic target. Adams J, Nat Rev Cancer 2004 4 349 360 10.1038/nrc1361 15122206
71. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. An B, Goldfarb RH, Siman R, et al. Cell Death Differ 1998 5 1062 1075 10.1038/sj.cdd.4400436 9894613
72. Tumor growth inhibition induced in a murine model of human Burkitts lymphoma by a proteasome inhibitor. Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Cancer Res 1998 58 4342 4348 9766662
73. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Masdehors P, Merle-Béral H, Maloum K, et al. Blood 2000 96 269 274 10891461
74. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. LeBlanc R, Catley LP, Hideshima T, et al. Cancer Res 2002 62 4996 5000 12208752
75. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Hideshima T, Richardson P, Chauhan D, et al. Cancer Res 2001 61 3071 3076 11306489
76. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. Zinzani PL, Musuraca G, Tani M, et al. J Clin Oncol 2007 25 27 4293 4297 10.1200/JCO.2007.11.4207 17709797
77. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Lee J, Suh C, Kang HJ, et al. Ann Oncol 2008 19 12 2079 2083 10.1093/annonc/mdn431 18689866
78. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Susan DD, Christopher JK, Monette A, et al. Cancer Res 2007 67 6383 6391 10.1158/0008-5472.CAN-06-4086 17616698
79. PX-171-004, a multicenter phase II study of carfilzomib in patients with relapsed myeloma: An efficacy update. Vij R, Wang M, Orlowski R, et al. J Clin Oncol 2009 27 15s bstract8537
80. Updated results of bortezomib-nave patients in PX-171-004, an ongoing open label, phase II study of single agent carfilzomib in patients with relapsed or refractory MM. Wang L, Siegel D, Kaufman JL, Blood 2009 ASH Annual meeting Abstracts 114:Abstract 302
81. Long-term treatment of CTCL with oral PNP inhibitor, forodesine. Duvic M, Forero-Torres A, Foss F, et al. J Clin Oncol 2009 27 15s bstract8552
82. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. Ginaldi L, Martinis M, Matutes E, et al. Leuk Res 1998 22 2 185 191 10.1016/S0145-2126(97) 00158-6 9593475
83. Mycosis fungoides/Sezary syndrome: a report of three cases treated with Campath-IH as salvage treatment. Capalbo S, Delia M, Dargenio M, et al. Medical Oncology 2003 20 389 396 10.1385/MO:20:4:389 14716037
84. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Kennedy GA, Seymour JF, Wolf M, et al. Eur J Haematol 2003 71 250 256 10.1034/j.1600-0609.2003.00143.x 12950233
85. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Lundin J, Hagberg H, Repp R, et al. Blood 2003 101 4267 4272 10.1182/blood-2002-09-2802 12543862
86. Successful treatment of chemotherapy refractory Sezary syndrome with alemtuzumab (Campath-1H). Gautschi O, Blumenthal N, Streit M, et al. Eur J Haematol 2004 72 61 63 10.1046/j.0902-4441.2004.00169.x 14962265
87. Alemtuzumb for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Querfeld C, Mehta N, Rosen T, et al. Leuk Lymphoma 2009 50 1969 1976 10.3109/10428190903216770 19860617
88. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Hale G, Rebello P, Brettman LR, et al. Blood 2004 104 948 955 10.1182/blood-2004-02-0593 15090452
89. Subcutaneous alemtuzumab for Sezary syndrome in the very elderly. Alinari L, Geskin L, Grady T, et al. Leuk Res 2008 32 1299 1303 10.1016/j.leukres.2007. 11.009 18096224
90. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Zinzani PL, Alinari L, Tani M, et al. Haematologica 2005 90 5 702 703 15921394
91. Low-dose of intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Bernengo MG, Quaglino P, Comessatti A, et al. Haematologica 2007 92 784 794 10.3324/haematol.11127 17550851
92. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Knox SJ, Levy R, Hodgkinson S, et al. Blood 1991 77 20 30 1984796
93. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Knox S, Hoppe RT, Maloney D, et al. Blood 1996 87 893 899 8562959
94. Clinical efficacy of zanolimumab (HuMax-CD4): two phase II studies in refractory cutaneous T-cell lymphoma. Kim Y, Duvic M, Obitz E, Blood 2007 109 4655 4662 10.1182/blood-2006-12-062877 17311990
95. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkins disease. Wahl AF, Klussman K, Thompson JD, et al. Cancer Res 2002 62 3736 3742 12097283
96. A phase I multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Bartlett NL, Younes A, Carabasi MH, et al. Blood 2008 111 1848 1854 10.1182/blood-2007-07-099317 18079362
97. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkins lymphoma and anaplastic large-cell lymphoma. Ansell SM, Horwitz SM, Engert A, et al. J Clin Oncol 2007 25 2764 2769 10.1200/JCO.2006.07.8972 17515574
98. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Younes A, Nat Rev Clin Oncol 2011 8 85 96 10.1038/nrclinonc.2010.189 21151205
99. A phase II study of SGN- 30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Duvic M, Reddy S, Pinter Brown L, et al. Clin Cancer Res 2009 15 9 6217 6224 10.1158/1078-0432.CCR-09-0162 19789316
100. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. Younes A, Bartlett NL, Leonard JP, et al. N Engl J Med 2010 363 1812 1821 10.1056/NEJMoa1002965 21047225
101. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). Bartlett NL, Forero-Torres A, Rosenblatt J, et al. ASCO Meeting Abstracts 2009 27 8500
102. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). Chen RW, Gopal AK, Smith SE, et al. ASCO Meeting Abstracts 2011 29 8031
103. Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Pro B, Advani R, Brice P, et al. ASCO Meeting Abstracts 2011 29 8032
104. EORTC 21012: Phase II multicenter study of CaelyxTM monotherapy in patients with advanced mycosis fungoides stage IIb, IVa and IVb with or without previous chemotherapy. Dummer R, Whittaker S, Hasan B, Blood 2010 ASH Annual Meeting Abstracts 116:Abstract 2823
105. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. Querfeld C, Rizvi MA, Kuzel TM, et al. J Invest Dermatol 2006 126 1641 1647 10.1038/sj.jid.5700322 16645590
106. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinse C beta inhibitor, in patients with advanced cancer. Carducci MA, Musib L, Kies MS, et al. J Clin Oncol 2006 24 4092 4099 10.1200/JCO.2005.05.3447 16943527
107. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Querfeld C, Kuzel TM, Kim YH, et al. Leuk Lymphoma 2011 52 8 1474 1480 10.3109/10428194.2011.572265 21649541
108. In situ vaccination of a TLR9 agonist induces systemic lymphoma regression. Brody J, Ai W, Czerwinski D, et al. J Clin Oncol 2010 28 28 4324 4332 10.1200/JCO.2010.28.9793 20697067
109. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase I/II study. Kim YH, Gratzinger D, Harrison C, Blood 2011 published ahead of print November 1
110. Lenalidomide (Revlimid) in patients with cutaneous T-cell lymphoma. Querfeld C, Kuzel TM, Guitart J, et al. Haematol Rep 2006 2 13 38 39